Cantargia Year-End Report January – December 2015

Cantargia AB (”Cantargia”) (STO:CANTA) Year-end report for January – December 2015 is available on the company web-site (www.cantargia.com). An extract from the report is presented below.

Significant events in the fourth quarter

· European Patent Office (EPO) issued an officially approved patent for IL1RAP as target molecule for antibody therapy and leukemia diagnostics.

· EPO had issued an intention to grant for the Company’s application concerning IL1RAP as a target molecule for antibody therapy and diagnostics of several types of solid tumours.

· David Liberg took up the position as Vice President Cancer Research.

· Selection of primary indications - non-small cell lung cancer and pancreatic cancer.

· Data from the first toxicity study had been obtained and showed no indications of toxicity in clinically relevant doses.

· Warrants of series 2010:1 were exercised, resulting in a dilution of around 0.8 per cent for existing shareholders.

Significant events after the end of the period

· Approval from EPO of the patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostics of several types of solid tumours.

· Approval in Australia for the patent application to use IL1RAP as target molecule for antibody treatment of haematological cancer diseases.

Financial information

Twelve months (1 Jan 2015 – 31 Dec 2015)

· Other operating revenue was KSEK 0 (0).

· Earnings after financial items were KSEK -17,190 (-8,370).

· Earnings per share were approximately SEK -1.27 (-0.62).

· The equity/assets ratio was approximately 89 (20) per cent.

Fourth quarter (1 Oct 2015 – 31 Dec 2015)

· Other operating revenue was KSEK 0 (0).

· Earnings after financial items were KSEK -5,003 (-2,547).

· Earnings per share were approximately SEK -0.37 (-0.19).

Definitions

Earnings per share: Profit for the period divided by 13,505,874 shares as of 31 December 2015.

Equity/assets ratio: Equity divided by total capital.

Figures in parentheses refer to the same period in the previous year.

The Interim report 1, for January – March 2016 will be presented May 16, 2016. Previously announced date was May 11, 2016.

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160229007085/en/